David Maag
Impact in
- Oncology top 2%
- PARP inhibition in cancer therapy
- Hepatology top 2%
- Hepatitis C virus research
Papers in
- Co-authors
- Jon R. Lorsch (9 shared papers)Craig E. Cameron (3 shared papers)Mikkel A. Algire (7 shared papers)Johnson Y. N. Lau (2 shared papers)Zhi Hong (2 shared papers)Weidong Zhong (2 shared papers)Jamie J. Arnold (1 shared paper)Shane Crotty (1 shared paper)
- Journals
- Annals of Oncology (5 papers)Cell (3 papers)Clinical Cancer Research (3 papers)ACS Medicinal Chemistry Letters (3 papers)Molecular Cell (3 papers)
- Partner nations
- United StatesAustraliaCanada
In The Last Decade
David Maag
52 papers receiving 5.7k citations
David Maag's Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 1.7k
- Hepatology 429
- Cancer Research 674
- Molecular Biology 3.0k
- Genetics 270
Countries citing papers authored by David Maag
This map shows the geographic impact of David Maag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Maag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Maag more than expected).
Fields of papers citing papers by David Maag
This network shows the impact of papers produced by David Maag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Maag. The network helps show where David Maag may publish in the future.
Co-authors
The 25 scholars most cited alongside David Maag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Hit paper breakdown → | 2000 | 689 |
| 2 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 614 |
| 3 | 2010 | 316 | |
| 4 | 2007 | 258 | |
| 5 | 2001 | 244 | |
| 6 | 2020 | 242 | |
| 7 | 2015 | 223 | |
| 8 | 2018 | 197 | |
| 9 | 2005 | 191 | |
| 10 | 2017 | 179 | |
| 11 | 2008 | 176 | |
| 12 | 2014 | 162 | |
| 13 | 2011 | 153 | |
| 14 | 2022 | 149 | |
| 15 | 2005 | 147 | |
| 16 | 2021 | 140 | |
| 17 | CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema Hit paper breakdown → | 2024 | 129 |
| 18 | 2011 | 122 | |
| 19 | 2002 | 120 | |
| 20 | 2017 | 114 |
About David Maag
David Maag is a scholar working on Genetics, Oncology, Molecular Biology, Cancer Research and Geriatrics and Gerontology, having authored 54 papers that have together received 5.9k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (11 papers), RNA and protein synthesis mechanisms (9 papers), RNA Research and Splicing (6 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers), Glioma Diagnosis and Treatment (5 papers), RNA modifications and cancer (5 papers), CRISPR and Genetic Engineering (4 papers) and Breast Cancer Treatment Studies (4 papers). The work is most often cited by research in Oncology (1.7k citations), Hepatology (429 citations), Cancer Research (674 citations), Molecular Biology (3.0k citations) and Genetics (270 citations). David Maag has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Jon R. Lorsch, Craig E. Cameron, Mikkel A. Algire, Johnson Y. N. Lau, Zhi Hong, Weidong Zhong, Jamie J. Arnold, Shane Crotty, Raul Andino and Zhi Hong. Their work appears in journals such as Annals of Oncology, Cell, Clinical Cancer Research, ACS Medicinal Chemistry Letters and Molecular Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.